FY2029 Earnings Forecast for ACXP Issued By HC Wainwright

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) – Investment analysts at HC Wainwright issued their FY2029 earnings estimates for Acurx Pharmaceuticals in a research note issued to investors on Wednesday, March 19th. HC Wainwright analyst E. Arce expects that the company will post earnings of ($0.57) per share for the year. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Acurx Pharmaceuticals’ current full-year earnings is ($0.89) per share.

Acurx Pharmaceuticals (NASDAQ:ACXP) last released its quarterly earnings data on Monday, March 17th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02.

Acurx Pharmaceuticals Stock Performance

Shares of Acurx Pharmaceuticals stock opened at $0.42 on Thursday. The firm has a 50-day moving average of $0.69 and a 200-day moving average of $1.26. The stock has a market cap of $8.22 million, a PE ratio of -0.38 and a beta of -1.71. Acurx Pharmaceuticals has a 52-week low of $0.40 and a 52-week high of $3.33.

Institutional Investors Weigh In On Acurx Pharmaceuticals

An institutional investor recently raised its position in Acurx Pharmaceuticals stock. Geode Capital Management LLC raised its stake in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 12.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 146,500 shares of the company’s stock after acquiring an additional 16,485 shares during the quarter. Geode Capital Management LLC owned approximately 0.90% of Acurx Pharmaceuticals worth $278,000 as of its most recent SEC filing. 11.53% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO David P. Luci acquired 49,261 shares of Acurx Pharmaceuticals stock in a transaction on Monday, January 6th. The shares were purchased at an average cost of $1.01 per share, for a total transaction of $49,753.61. Following the completion of the purchase, the chief executive officer now directly owns 1,097,458 shares of the company’s stock, valued at approximately $1,108,432.58. This represents a 4.70 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 29.60% of the stock is currently owned by company insiders.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.